Vertex PharmaceuticalsVRTX
NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation
American biotech company and global leader in cystic fibrosis treatment, with a pipeline in pain and gene therapy.
Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.
Key metrics
Market cap
$130B
Price
$486.44
Today
−2.0%
Return YTD
+9.5%
Return 1Y
+3.7%
P/E
30.0
P/S
10.7
P/B
6.7
Data as of 2026-07-10 · updates daily after U.S. close
Theme exposure
In the value chain
Products & services
- Cystic fibrosis
- Pain treatment
- Cell & gene therapy (Casgevy)
Competitors
- Other CF players
- Gene therapy biotechs
Risks
- Concentration in CF franchise
- Pipeline execution
Same segment: Biotech & innovation
See where Vertex Pharmaceuticals sits in the full Medicine, pharma & life science map — every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →